HK1253316A1 - 肽 - Google Patents
肽Info
- Publication number
- HK1253316A1 HK1253316A1 HK18112609.8A HK18112609A HK1253316A1 HK 1253316 A1 HK1253316 A1 HK 1253316A1 HK 18112609 A HK18112609 A HK 18112609A HK 1253316 A1 HK1253316 A1 HK 1253316A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- peptides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/8142—Aspartate protease (E.C. 3.4.23) inhibitors, e.g. HIV protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14195323 | 2014-11-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1253316A1 true HK1253316A1 (zh) | 2019-06-14 |
Family
ID=52000704
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK18112609.8A HK1253316A1 (zh) | 2014-11-28 | 2018-10-02 | 肽 |
Country Status (6)
Country | Link |
---|---|
US (1) | US10683329B2 (zh) |
EP (1) | EP3224271B1 (zh) |
JP (1) | JP6691914B2 (zh) |
CN (1) | CN108064232B (zh) |
HK (1) | HK1253316A1 (zh) |
WO (1) | WO2016083425A1 (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017016982A1 (en) * | 2015-07-24 | 2017-02-02 | F. Hoffmann-La Roche Ag | Bace1 inhibitor peptides |
WO2019094608A1 (en) | 2017-11-08 | 2019-05-16 | Denali Therapeutics Inc. | Anti-bace1 antibodies and methods of use thereof |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070149763A1 (en) * | 2003-10-15 | 2007-06-28 | Bristol-Myers Squibb Company | Beta secretase exosite binding peptides and methods for identifying beta secretase modulators |
EP2119455A1 (en) | 2004-04-08 | 2009-11-18 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Tripartite raftophilic structures and their use |
JP4896870B2 (ja) * | 2004-04-08 | 2012-03-14 | ヤード・テヒノロギース・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 細胞膜ラフトと相互作用する構造を含む三者複合体およびその使用 |
US8815841B2 (en) * | 2011-02-18 | 2014-08-26 | Hoffmann-La Roche Inc. | 1,4-Oxazepines as BACE1 and/or BACE2 inhibitors |
EP2766028B1 (en) * | 2011-10-14 | 2017-08-16 | F. Hoffmann-La Roche AG | Peptide inhibitors of bace1 |
JP6435321B2 (ja) * | 2013-06-12 | 2018-12-05 | ヤンセン ファーマシューティカ エヌ.ベー. | β−セクレターゼ(BACE)の阻害剤としての4−アミノ−6−フェニル−6,7−ジヒドロ[1,2,3]トリアゾロ[1,5−A]ピラジン誘導体 |
EP3224272B1 (en) * | 2014-11-28 | 2019-08-21 | F.Hoffmann-La Roche Ag | Peptides |
-
2015
- 2015-11-25 EP EP15800821.9A patent/EP3224271B1/en not_active Not-in-force
- 2015-11-25 CN CN201580060813.2A patent/CN108064232B/zh active Active
- 2015-11-25 WO PCT/EP2015/077581 patent/WO2016083425A1/en active Application Filing
- 2015-11-25 US US15/527,917 patent/US10683329B2/en active Active
- 2015-11-25 JP JP2017528479A patent/JP6691914B2/ja not_active Expired - Fee Related
-
2018
- 2018-10-02 HK HK18112609.8A patent/HK1253316A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
JP6691914B2 (ja) | 2020-05-13 |
CN108064232B (zh) | 2021-06-15 |
WO2016083425A1 (en) | 2016-06-02 |
US10683329B2 (en) | 2020-06-16 |
CN108064232A (zh) | 2018-05-22 |
EP3224271A1 (en) | 2017-10-04 |
US20180312541A1 (en) | 2018-11-01 |
JP2017537098A (ja) | 2017-12-14 |
EP3224271B1 (en) | 2019-09-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB201418562D0 (en) | Peptides | |
GB201520559D0 (en) | Peptides | |
GB201520536D0 (en) | Peptides | |
GB201401877D0 (en) | Peptides | |
GB201520545D0 (en) | Peptides | |
GB201520546D0 (en) | Peptides | |
GB201520550D0 (en) | Peptides | |
GB201520543D0 (en) | Peptides | |
GB201520563D0 (en) | Peptides | |
GB201520544D0 (en) | Peptides | |
GB201520562D0 (en) | Peptides | |
GB201520541D0 (en) | Peptides | |
GB201520539D0 (en) | Peptides | |
GB201520567D0 (en) | Peptides | |
HK1253316A1 (zh) | 肽 | |
GB201503483D0 (en) | Novel Antimmicrobial Peptides | |
GB201520568D0 (en) | Peptides | |
GB201520570D0 (en) | Peptides | |
GB201520566D0 (en) | Peptides | |
GB201520542D0 (en) | Peptides | |
GB201520558D0 (en) | Peptides | |
GB201520564D0 (en) | Peptides | |
GB201520557D0 (en) | Peptides | |
GB201520548D0 (en) | Peptides | |
GB201520552D0 (en) | Peptides |